Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT201 in advanced gynecologic tumors
NCT05724732Phase 1Unknown
- Sponsor
- Renji Hospital
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT201 in Cervical Cancer (CC), ovarian cancer and endometrial cancer (EC), sponsored by Renji Hospital. Primary endpoint: Safety Profile Measured by Grade >=3 TEAEs at 3 years. Status: unknown.
02
Drugs
GT201
03
Conditions
Cervical Cancer (CC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT05724732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724732.